Absci Corp (ABSI)
3.98
-0.39
(-8.92%)
USD |
NASDAQ |
Jun 14, 16:00
4.00
+0.02
(+0.50%)
After-Hours: 20:00
Absci Cash from Operations (Quarterly): -17.86M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -17.86M |
| December 31, 2023 | -14.92M |
| September 30, 2023 | -10.36M |
| June 30, 2023 | -19.23M |
| March 31, 2023 | -20.12M |
| December 31, 2022 | -18.57M |
| September 30, 2022 | -19.04M |
| June 30, 2022 | -22.58M |
| March 31, 2022 | -21.15M |
| Date | Value |
|---|---|
| December 31, 2021 | -17.08M |
| September 30, 2021 | -21.75M |
| June 30, 2021 | -14.49M |
| March 31, 2021 | -7.285M |
| December 31, 2020 | -2.521M |
| September 30, 2020 | -2.708M |
| June 30, 2020 | -3.312M |
| March 31, 2020 | -2.429M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-22.58M
Minimum
Jun 2022
-2.429M
Maximum
Mar 2020
-13.85M
Average
-17.08M
Median
Dec 2021
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly and Co | 1.166B |
| CytomX Therapeutics Inc | -26.04M |
| Bristol-Myers Squibb Co | 2.834B |
| Recursion Pharmaceuticals Inc | -102.30M |
| NovaBay Pharmaceuticals Inc | -1.572M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -76.68M |
| Cash from Financing (Quarterly) | 81.18M |
| Free Cash Flow | -62.38M |
| Free Cash Flow Per Share (Quarterly) | -0.1797 |
| Free Cash Flow to Equity (Quarterly) | -16.99M |
| Free Cash Flow to Firm (Quarterly) | -17.69M |
| Free Cash Flow Yield | -16.67% |